Pain Management Drugs Market to Surpass US$ 105,252.1 Mn by 2030

Global Pain Management Drugs Market, by Drug Class (Opioids, NSAIDs, Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 76,415.7 Million in 2022 and is expected to exhibit a CAGR of 4.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Availability of large number of pain management drug products (generic as well as branded), absence of alternative therapies, and ongoing research and development of different therapies is expected to fuel growth of the pain management drugs market. Lupin Pharmaceuticals launched generic pain medication of Allergan’s Norco (hydrocodone/acetaminophen) in 2017 in the U.S. Daiichi Sankyo Company, Limited announced launch of Narurapid (hydromorphone hydrochloride) tablets and Narusus tablets for cancer pain treatment in 2017. Flexion Therapeutics Inc. received the U.S. Food & Drug Administration (FDA) approval for drug Zilretta osteoarthritis knee pain in 2017. Manufacturers are indulged in integrating healthcare IT, in order to help physicians with pain management. For instance, digital therapeutic company 2Morrow, Inc. launched an app for pain management in February 2018. Avella launched pain and addiction management mobile app for physicians in 2017. These applications will help physicians in management of their patients along with curbing the opioid (drugs taken in pain management) addiction problems. This is expected to increase the adoption rate of pain management drugs over the forecast period, thereby, driving growth of pain management drugs market.

Global Pain Management Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the global pain management drugs market, owing to increasing demand of Non-steroidal anti-inflammatory drugs due to its possible association with the COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, the common symptoms associated with Covid-19 are fever, mild colds, headache, and throat pain. The medication should be considered alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in the management of mild-to-moderate pain as part of multimodal analgesia. Paracetamol can also be used safely to alleviate symptoms of COVID-19 such as fever, headache, and acute or chronic pain. Non-selective NSAIDs (e.g., ibuprofen, naproxen, and indomethacin) are effective for mild-to-moderate pain through inhibition of cyclo-oxygenage-1 (COX-1) and cyclo-oxygenage-2 (COX-2) enzymes leading to a reduction of prostaglandins. Prostaglandins mediate pain, fever, inflammation, and swelling, and have a key role in gastric protection and hemostasis.

Global Pain Management Drugs Market: Key Developments

In June 2022, according to data published by Heron Therapeutics, Inc., ZYNRELEF (bupivacaine and meloxicam) was initially approved by the U. S. Food and Drug Administration (FDA) in May 2021 and in December 2021, the U. S. Food and Drug Administration (FDA) approved an expansion of ZYNRELEF’s indication. In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. As of January 1, 2021, ZYNRELEF was approved in 31 European countries including the countries of the European Union and European Economic Area and the U.K. ZYNRELEF is formulated in Heron’s proprietary controlled-diffusion Biochronomer polymer for consistently regulated delivery of bupivacaine and meloxicam. In March 2022, Health Canada issued a Notice of Compliance for ZYNRELEF for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.

Browse 34 Market Data Tables and 55 Figures spread through 205 Pages and in-depth TOC on “Global Pain Management Drugs Market”- Forecast to 2030, Global Pain Management Drugs Market, by Drug Class (Opioids, NSAIDs, Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights related to Global Pain Management Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pain-management-devices-market-3947

Moreover, ongoing research and development for novel pain management medications is expected to boost the market growth over the forecast period. For instance, in May 2022, Trevena, Inc., a biopharmaceutical company, Oliceridine injection for moderate to severe acute pain (New Drug Application -NDA approved by the U. S. Food and Drug Administration (U.S.FDA) in January 2018), and TRV734 (Phase I) for moderate to severe pain. In collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy with potential application to other rare or orphan seizure disorders. Trevena, Inc. has one approved product in the U.S., OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain, severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Key Takeaways of the Global Pain Management Drugs Market:

• Global pain management drugs market is expected to exhibit a CAGR of 4.1% during the forecast period due to increasing adoption of inorganic strategies such as acquisition by key players in market for developing pain management drugs. For instance, on May 10 2022, Pfizer Inc. ,a pharmaceutical and biotechnology corporation acquired Biohaven Pharmaceuticals, a development and commercialization company, the maker of NURTEC ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. The acquisition ensures increase in the production of the NURTEC ODT used for acute treatment of migraine in adults.
• Among drug class, opioids segment is expected to dominate the pain management drugs market over the forecast period. For instance, on April 27 2022, Opioid Analgesic Stewardship in Acute Pain Clinical Care Standard described the key components of care that patients can expect when they are prescribed opioid analgesics for acute pain in acute care settings. Opioid analgesics are high-risk medicines, widely used in hospitals and primary care to manage pain. This new national standard will help to ensure the appropriate use and review of opioid analgesics for the management of acute pain to optimize patient outcomes and reduce the potential for opioid-related harm in Australia. In April 2020, the Therapeutic Goods Administration (TGA) engaged the Commission to develop a framework for a National Opioid Analgesic Stewardship program, and an accompanying clinical care standard, which together support the opioid analgesic regulatory changes. The aim of the Therapeutic Goods Administration (TGA) regulatory changes, the National Opioid Analgesics Stewardship program and the accompanying clinical care standard is to minimize the risk of harm associated with opioid analgesic use.
• Among regions, North America is estimated to account for the largest market share in the global pain management drugs market over the forecast period, owing to high prevalence of chronic pain diseases. For instance, in September 2018, according to data published by National Health Interview Survey, 20.4% (50.0 million) of the U.S. adults had chronic pain and 8.0% of U.S. adults (19.6 million) had high-impact chronic pain, with higher prevalence of both chronic pain and high-impact chronic pain reported among women, older adults.
• Major players operating in the global pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.